1. Home
  2. TRDA vs WNC Comparison

TRDA vs WNC Comparison

Compare TRDA & WNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$12.53

Market Cap

438.8M

Sector

Health Care

ML Signal

HOLD

WNC

Wabash National Corporation

HOLD

Current Price

$9.86

Market Cap

397.9M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRDA
WNC
Founded
2016
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Construction/Ag Equipment/Trucks
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
438.8M
397.9M
IPO Year
2021
2009

Fundamental Metrics

Financial Performance
Metric
TRDA
WNC
Price
$12.53
$9.86
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$20.00
$11.00
AVG Volume (30 Days)
178.8K
675.9K
Earning Date
05-25-2026
05-05-2026
Dividend Yield
N/A
3.34%
EPS Growth
N/A
179.22
EPS
N/A
5.07
Revenue
$25,421,000.00
$2,027,489,000.00
Revenue This Year
$51.37
$0.53
Revenue Next Year
$46.98
$25.53
P/E Ratio
N/A
$1.89
Revenue Growth
N/A
8.81
52 Week Low
$4.93
$6.78
52 Week High
$12.93
$12.94

Technical Indicators

Market Signals
Indicator
TRDA
WNC
Relative Strength Index (RSI) 62.04 40.37
Support Level $9.59 $9.49
Resistance Level N/A $11.50
Average True Range (ATR) 0.78 0.59
MACD 0.09 -0.24
Stochastic Oscillator 83.06 18.23

Price Performance

Historical Comparison
TRDA
WNC

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About WNC Wabash National Corporation

Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.

Share on Social Networks: